Floatz logo

ANTI-CD32B MONOCLONAL ANTIBODY BI-1206

Chronic Lymphocytic Leukaemia

Cancer Research UKmonoclonal_antibodyPhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

72 Active assets in the Chronic Lymphocytic Leukaemia cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Emory University
Phase 4BBB
Acalabrutinib
Zulfa Omer
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

ANTI-CD32B MONOCLONAL ANTIBODY BI-1206 is also rated in:

Waldenstrom macroglobulinemiaDormant
CCC
Indicative ·
50 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →